TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30089762
Drug: Del Nido
Normalized name: Del Nido Cardioplegia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Del Nido solution (DNS)
Study: 19661687
Drug: 15 ml
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml of vinegar (750 mg AcOH)
Study: 19661687
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml of vinegar (1,500 mg AcOH)
Study: 19661687
Drug: 0 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 ml of vinegar (0 mg AcOH, placebo)
Study: 11888224
Drug: Venlafaxine (18.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (18.75 mg daily, increased by one tablet at 1 week intervals)
Study: 9863332
Drug: Endocervical application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocervical application of 0.5 mg Dinoprostone (Group I)
Study: 9863332
Drug: Intravenous application
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous application of Syntocinon (Group II)
Study: 7675391
Drug: Heparin (anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (anticoagulant of choice)
Study: 2116057
Drug: Thyrotropin-releasing hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin-releasing hormone (200 micrograms, as an i.v. bolus)
Study: 146331
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus heparin
Study: 28004188
Drug: Paracetamol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (15 mg/kg/6 h IV infusion for 3 days)
Study: 28004188
Drug: Ibuprofen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (10 mg/kg IV infusion followed by 5 mg/kg/day for 2 days)
Study: 28004188
Drug: Indomethacin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (0.2 mg/kg/12 h IV infusion for three doses)
Study: 22018631
Drug: Letrozole monotherapy
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole monotherapy for 5 years
Study: 22018631
Drug: Tamoxifen monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen monotherapy for 5 years
Study: 19886855
Drug: Irbesartan/HCTZ 150/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan/HCTZ 150/12.5 mg to 300/25 mg
Study: 9768826
Drug: Dexrazoxane (DEX)
Normalized name: Dexrazoxane
DrugBank: Dexrazoxane (DB00380)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexrazoxane (DEX) administered 30 minutes before daunorubicin (DNR) 45 mg/m2 or mitoxantrone (MTX) 10 mg/m2, in doses 8-13 times higher for DNR or 30-60 times higher for MTX, with a treatment cycle including 10 high doses (2,000 mg/m2/12 hr) of cytosine arabinoside plus two doses of DNR or MTX on days 4 and 5.
Study: 9768826
Drug: Dexrazoxane (DEX)
Normalized name: Dexrazoxane
DrugBank: Dexrazoxane (DB00380)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexrazoxane (DEX) as a cardioprotective agent during chemotherapy.
Study: 9768826
Drug: Delayed administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed administration of DEX after cumulative doses of DNR 500 mg/m2.
Study: 9768826
Drug: Chemotherapy regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimen including DEX, DNR, MTX, and cytosine arabinoside.
Study: 408860
Drug: L-tryptophan treatment
Normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-tryptophan treatment
Study: 30901920
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg nicotine of TC (3TC)
Study: 30901920
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg nicotine of EC (3EC)
Study: 30901920
Drug: Control 0
Normalized name: Mane 'N Tail Daily Control 0.5 % Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control 0 mg nicotine of EC (C)
Study: 22301466
Drug: 24-week pegylated
Normalized name: Pegylated rfviii
DrugBank: PEGylated Recombinant Factor VIII (DB16093)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-week pegylated interferon plus ribavirin therapy
Study: 16763372
Drug: Each 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 5 mumol/l increment in homocysteine levels
Study: 16303792
Drug: Docetaxel (66
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (66 mg/m² Day 1)
Study: 16303792
Drug: Docetaxel (33
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (33 mg/m² Days 1 and 8)
Study: 16303792
Drug: Arm A
Normalized name: Warm antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A (66 mg/m² Day 1)
Study: 16303792
Drug: Arm B
Normalized name: arm brace
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B (33 mg/m² Days 1 and 8)
Study: 16303792
Drug: Response to
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Response to front-line chemotherapy
Study: 10155119
Drug: Perfusion angioplasty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perfusion angioplasty as a primary treatment strategy
Study: 2288830
Drug: 50 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml cream (20 g fat) preload with placebo
Study: 2288830
Drug: 50 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml cream (20 g fat) preload with 10 mg cisapride
Study: 2288830
Drug: 50 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml water preload with placebo
Study: 27764906
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2 IV on D1 (D)
Study: 27764906
Drug: Docetaxel 60
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 60 mg/m2 IV plus cisplatin 60 mg/m² IV on D1 (DC)
Study: 27764906
Drug: Docetaxel 60
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 60 mg/m2 IV D1 plus oral S-1 30 mg/m2 twice a day on D1-14 (DS)
Study: 27488051
Drug: L-citrulline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-citrulline and metformin therapy for 26 weeks
Study: 27488051
Drug: L-citrulline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-citrulline and metformin therapy
Study: 17442681
Drug: Acetaminophen (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1000 mg) + Caffeine (130 mg)
Study: 17442681
Drug: Caffeine (130
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (130 mg)
Study: 11817529
Drug: Heparin-coated (HC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated (HC) VVBP equipment
Study: 9585294
Drug: Lornoxicam (Xefo;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam (Xefo; administered i.v. via PCA for up to 24 h)
Study: 9585294
Drug: Morphine (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (administered i.v. via PCA for up to 24 h)
Study: 30274699
Drug: Radiofrequency-induced thermo-chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiofrequency-induced thermo-chemotherapy effect (RITE) with 40mg mitomycin-C at 42±2°C for 60 minutes
Study: 30274699
Drug: Radiofrequency-induced thermo-chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiofrequency-induced thermo-chemotherapy effect (RITE)
Study: 30274699
Drug: Control (institutional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (institutional standard second-line therapy)
Study: 26970266
Drug: Armodafinil (150-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armodafinil (150-200 mg/day)
Study: 18465241
Drug: Ingesting 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingesting 500 ml of polyethylene glycol (PEG) starting 30 min after swallowing the capsule
Study: 18465241
Drug: No preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preparation (control group A)
Study: 16371776
Drug: Topical cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporine A 0.05% (tCsA)
Study: 9004052
Drug: Doxepin (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin (mean daily dosage at 6 weeks 169 +/- 42 mg)
Study: 9004052
Drug: Fluoxetine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (mean daily dosage at 6 weeks 37 +/- 18 mg)
Study: 8285374
Drug: Felodipine 10
Normalized name: felodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 10 mg (plain tablet)
Study: 3100877
Drug: Beclomethasone nasal
Normalized name: beclomethasone nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone nasal solution
Study: 30636826
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg melatonin tablets 45 min before sleep for 3 days after surgery
Study: 22697189
Drug: Aripiprazole-IM-depot (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole-IM-depot (400 mg every 4 weeks, with coadministration of oral aripiprazole for the first 2 weeks)
Study: 17324600
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (rhGH) 0.058 IU/kg/day for 6 days
Study: 16246996
Drug: Nortriptyline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline (75 mg once daily)
Study: 11893367
Drug: Antiresorptive drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiresorptive drugs (e.g., alendronate)
Study: 11893367
Drug: Antiresorptive treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiresorptive treatments (general)
Study: 8154632
Drug: Albuterol via
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol via metered dose inhaler (MDI)
Study: 8154632
Drug: Albuterol via
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol via AeroChamber
Study: 8154632
Drug: Albuterol via
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol via OptiHaler
Study: 8154632
Drug: Placebo via
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo via metered dose inhaler (MDI)
Study: 22256669
Drug: Vertical/horizontal combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vertical/horizontal combination grab bar configuration
Study: 22256669
Drug: L-shaped bar
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-shaped bar configuration
Study: 22256669
Drug: Vertical/angled combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vertical/angled combination grab bar configuration
Study: 21429720
Drug: 15-g soy
Normalized name: SOY ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-g soy protein and 100-mg isoflavone
Study: 21429720
Drug: 15-g milk
Normalized name: magnesium hydroxide
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15-g milk protein and 100-mg isoflavone
Study: 21429720
Drug: 15-g milk
Normalized name: magnesium hydroxide
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15-g milk protein (placebo group)
Study: 18462730
Drug: Myo-inositol combined
Normalized name: myo-inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Myo-inositol combined with folic acid (Inofolic) 2 g twice a day
Study: 17552953
Drug: 1-day ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-day ciprofloxacin XR 1000 mg
Study: 17552953
Drug: 3-day ciprofloxacin
Normalized name: ciprofloxacin 3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day ciprofloxacin XR 1000 mg
Study: 7835330
Drug: FE-27 (27
Approvals — FDA: no, EMA: no, PMDA: no
Description: FE-27 (27 mg iron x day‐1)
Study: 7835330
Drug: FE-9 (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: FE-9 (9 mg iron x day‐1)
Study: 31841023
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) for 8 weeks
Study: 29063521
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy (MBCT) for 8 weeks
Study: 31841023
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) and Mindfulness-based cognitive therapy (MBCT)
Study: 28254462
Drug: ASP3652 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP3652 25 mg twice daily
Study: 28254462
Drug: ASP3652 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP3652 75 mg, 150 mg, or 300 mg once daily
Study: 28254462
Drug: ASP3652 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP3652 (all doses)
Study: 21547897
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide (CYC) treatment for 12 months
Study: 18001798
Drug: Intravesical pentosan
Normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravesical pentosan polysulfate sodium plus oral pentosan polysulfate sodium
Study: 18001798
Drug: Intravesical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical placebo plus oral pentosan polysulfate sodium
Study: 14602435
Drug: Parent-initiated oral
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-initiated oral prednisolone (20 mg once daily for 5 days)
Study: 27055257
Drug: Medical device
Normalized name: EndeavoRx Digital Medical Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical device (MD; a capsule whose main component is a cross‐linked protein)
Study: 27055257
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg/day and 1 capsule/day
Study: 24665980
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Transmetil 1000 mg/d or Essentiale 1368 mg/d)
Study: 17519049
Drug: lornoxicam 16
Normalized name: Lornoxicam 16 mg prolonged-release oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: lornoxicam 16 mg
Study: 17519049
Drug: tenoxicam 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: tenoxicam 40 mg
Study: 15226623
Drug: Ticlopidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (200 mg/day) plus aspirin (81 mg/day)
Study: 15226623
Drug: Cilostazol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (200 mg/day) plus aspirin (81 mg/day)
Study: 23555538
Drug: Ticlopidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (200 mg/day)
Study: 7925336
Drug: Pethidine 1
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine 1 mg kg‐1 and atropine 0.02 mg kg‐1 intramuscularly 90 min prior to surgery (n = 10)
Study: 7925336
Drug: Midazolam 0.5
Normalized name: midazolam 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.5 mg kg‐1 and atropine 0.02 mg kg‐1 orally, 120 min before surgery (n = 10)
Study: 2697552
Drug: Lactitol (19
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactitol (19 g anhydrous)
Study: 2697552
Drug: Lactulose (19
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (19 g)
Study: 2697552
Drug: Other test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other test compounds (Sorbitol 10 g, Mannitol 10 g, Maltitol 19 g, Palatinit 19 g anhydrous)
Study: 28183583
Drug: Patients on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients on antidepressants (n=76)
Study: 23547849
Drug: Tocilizumab 162
Normalized name: TOCILIZUMAB 162MG/0.9ML AUTOINJECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab 162 mg
Study: 23547849
Drug: Tocilizumab 162
Normalized name: TOCILIZUMAB 162MG/0.9ML AUTOINJECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab 162 mg with rHuPH20
Study: 23547849
Drug: Tocilizumab 324
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab 324 mg with rHuPH20
Study: 23547849
Drug: Tocilizumab 648
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab 648 mg with rHuPH20
Study: 23547849
Drug: Increasing doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing doses of tocilizumab
Study: 21714883
Drug: Care management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Care management intervention involving comprehensive assessment of medical and non-medical needs, regular structured monitoring of symptoms, written information, symptom diaries, action plans, and a medication plan for self-management capabilities.
Study: 12390096
Drug: Tegaserod, 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod, 6 mg b.d. (n = 767)
Study: 10191213
Drug: Candidate HIV-1
Normalized name: Remune HIV-1
DrugBank: Remune (DB17772)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candidate HIV-1 vaccine
Study: 2263428
Drug: Regimen A
Normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A (52 doses)
Study: 2263428
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (94 doses)
Study: 30109443
Drug: G‐Premio Bond
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐Premio Bond (GP)
Study: 23605128
Drug: Electrical Stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical Stimulation Therapy (EST) on the suprahyoid muscle only (SM)
Study: 23605128
Drug: Electrical Stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical Stimulation Therapy (EST) with one pair of electrodes on the suprahyoid muscle and another pair on the infrahyoid muscle (SI)
Study: 9517646
Drug: 4-day low
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4-day low dose triple therapy (LAT group): lansoprazole 30 mg b.i.d. on days 1-4, azithromycin 500 mg u.i.d. on days 2-4, tinidazole 2000 mg u.i.d. on day 3
Study: 9517646
Drug: 1-week triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-week triple therapy (OCT group): omeprazole 20 mg u.i.d., clarithromycin 250 mg b.i.d., tinidazole 500 mg b.i.d.
Study: 3132244
Drug: Combined oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oestrogen and progestogen (sequential supplementation)
Study: 29191714
Drug: Subcutaneous immunoglobulins
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunoglobulins
Study: 28176220
Drug: Intravenous glucocorticoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucocorticoids (ivGCs) - methylprednisolone with cumulative doses of 2.25, 4.98, 7.47 g
Study: 21934371
Drug: P group
Normalized name: P & S
Approvals — FDA: no, EMA: no, PMDA: no
Description: P group (random surface tilt perturbations, 3 times weekly for 3 weeks)
Study: 21934371
Drug: P+EX group
Approvals — FDA: no, EMA: no, PMDA: no
Description: P+EX group (random surface tilt perturbations + home vestibular rehabilitation exercises, 3 times weekly for 3 weeks)
Study: 19145673
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ketoprofen i.v. every 8h for 72h
Study: 19145673
Drug: 2.5 g
Normalized name: Vaporizer 2.5 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g metamizole i.v. every 8h for 72h
Study: 12042687
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (n = 77)
Study: 1940775
Drug: Lovastatin 20
Normalized name: lovastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 20 mg nightly in non-FH patients
Study: 1940775
Drug: Lovastatin 40
Normalized name: lovastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 40 mg nightly in FH patients
Study: 1940775
Drug: Lovastatin 40
Normalized name: lovastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 40 mg nightly in pooled patients (n = 224)
Study: 19056606
Drug: L-carnitine 2
Normalized name: L-Carnitine 250mg Oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine 2 g once daily
Study: 11486790
Drug: Orlistat (OLS)
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat (OLS) 120 mg three times daily
Study: 9349964
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment with 'Flowtron DVT' garments followed by Enoxaparin
Study: 8252746
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine oestrogen (1.25 mg Premarin)
Study: 8252746
Drug: Oestradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oestradiol valerate (2 mg)
Study: 3545477
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg metolazone
Study: 3545477
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg metolazone
Study: 3545477
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg metolazone
Study: 3545477
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg older metolazone
Study: 30706426
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec U100
Study: 24891437
Drug: Intravenous ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ferric carboxymaltose (FCM) targeting high ferritin (400-600 µg/L)
Study: 24891437
Drug: Intravenous ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ferric carboxymaltose (FCM) targeting low ferritin (100-200 µg/L)
Study: 20308250
Drug: N-Acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-Acetylcysteine (NAC) infusion at 125 mg kg(1) h(1) for 15 min and then at 25 mg kg(1) h(1) for 20 min before and throughout exercise
Study: 12470771
Drug: Bradykinin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bradykinin (10 microg intradermal injection)
Study: 30045423
Drug: Milk fortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk fortified with beverage powder containing 7 mg isotopically labeled iron (57Fe/58Fe) as Fe4(P2O7)3 and equimolar proportions of ascorbic acid
Study: 24615745
Drug: AC (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC (100 mg aspirin plus 75 mg clopidogrel)